Joel Rousseau
Overview
Explore the profile of Joel Rousseau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
BenDavid E, Ramezanian S, Lu Y, Rousseau J, Schroeder A, Lavertu M, et al.
Pharmaceuticals (Basel)
. 2024 Jun;
17(6).
PMID: 38931430
Prime editing shows potential as a precision genome editing technology, as well as the potential to advance the development of next-generation nanomedicine for addressing neurological disorders. However, turning in prime...
2.
Godbout K, Rousseau J, Tremblay J
Cells
. 2024 Jan;
13(1).
PMID: 38201236
We report the first correction from prime editing a mutation in the gene, paving the way to gene therapies for RYR1-related myopathies. The gene codes for a calcium channel named...
3.
Happi Mbakam C, Roustant J, Rousseau J, Yameogo P, Lu Y, Bigot A, et al.
Front Med (Lausanne)
. 2023 Jun;
10:1128557.
PMID: 37305116
Duchenne muscular dystrophy is a rare and lethal hereditary disease responsible for progressive muscle wasting due to mutations in the gene. We used the CRISPR-Cas9 Prime editing technology to develop...
4.
Happi Mbakam C, Rousseau J, Lu Y, Bigot A, Mamchaoui K, Mouly V, et al.
Mol Ther Nucleic Acids
. 2022 Nov;
30:272-285.
PMID: 36320324
Duchenne muscular dystrophy is a severe debilitating genetic disease caused by different mutations in the gene leading to the absence of dystrophin protein under the sarcolemma. We used CRISPR-Cas9 prime...
5.
Happi Mbakam C, Rousseau J, Tremblay G, Yameogo P, Tremblay J
Int J Mol Sci
. 2022 Jun;
23(11).
PMID: 35682838
The Prime editing technique derived from the CRISPR/Cas9 discovery permits the modification of selected nucleotides in a specific gene. We used it to insert specific point mutations in exons 9,...
6.
Majeau N, Fortin-Archambault A, Gerard C, Rousseau J, Yameogo P, Tremblay J
Mol Ther
. 2022 May;
30(7):2429-2442.
PMID: 35619556
Extracellular vesicles (EVs) mediate intercellular biomolecule exchanges in the body, making them promising delivery vehicles for therapeutic cargo. Genetic engineering by the CRISPR system is an interesting therapeutic avenue for...
7.
Tremblay G, Rousseau J, Happi Mbakam C, Tremblay J
CRISPR J
. 2022 Feb;
5(1):109-122.
PMID: 35133877
Alzheimer's disease (AD) is the result of abnormal processing of the amyloid precursor protein (APP) by β-secretase and γ-secretase, which leads to the formation of toxic β-amyloid peptides. The toxic...
8.
Guyon A, Rousseau J, Begin F, Bertin T, Lamothe G, Tremblay J
Mol Ther Nucleic Acids
. 2021 Apr;
24:253-263.
PMID: 33815938
The amyloid precursor protein () is a transmembrane protein mostly found in neurons. Cleavage of this protein by β-secretase can lead to the formation of amyloid-β (Aβ) peptide plaque, which...
9.
Guyon A, Rousseau J, Lamothe G, Tremblay J
PLoS One
. 2020 Dec;
15(12):e0237122.
PMID: 33370284
The deposition of Aβ plaques in the brain leads to the onset and development of Alzheimer's disease. The Amyloid precursor protein (APP) is cleaved by α-secretase (non-amyloidogenic processing of APP),...
10.
Cherif K, Gerard C, Rousseau J, Ouellet D, Chapdelaine P, Tremblay J
Mol Ther Nucleic Acids
. 2018 Sep;
12:19-32.
PMID: 30195758
Frataxin gene (FXN) expression is reduced in Friedreich's ataxia patients due to an increase in the number of GAA trinucleotides in intron 1. The frataxin protein, encoded by that gene,...